3[4]Gispert J, Antonijoan R, Barbanoj M, et al. Efficacy of ebastine,cetirizine, and loratadine in histamine cutaneous challenges[J]. Ann Allergy Asthma Immunol, 2002, 89(3): 259-364.
4[5]Malik M. Problems of heart rate correction in assessment of druginduced QT interval prolongation[J]. J Cardiovasc Electrophysiol,2001, 12(4): 411-420.
5[6]Hindmarch I, Shamsi Z. Antihistamine: models to assess sedative properties, assessment of sedation, safety and other side-effects[J]. Clin Exp Allergy, 1999, 29(3): 133-142.
6Grattan CE, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria-a clinical, immunological and histological evaluation[J]. Br J Dermatol, 1986, 114(5): 583- 590.
7Grattan CE, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with function properties of anti-IgE in chronic urticaria[J]. Clin Exp Allergy, 1991, 21(6): 695-704.
8Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause for histamin release in chronic urticaria[J]. N Engl J Med, 1993, 328(22): 1599-1604.
9Horn MP, Pachlopnik JM, Vogel M, et al. Conditional autoimmunity mediated by human natural anti-Fc (epsilon) Rialpha autoantibodies?[J]. FASEB J, 2001, 15(12): 2268-2274.
10Ferrer M, Nakazama K, Kaplan AP. Complement dependence of histamin release in chronic urticaria[J]. J Allergy Clin Immunol, 1999, 104(1): 169-172.
